Expat
1.2K posts

Expat
@0xFiatToZero
Alex Moody = Somali Daycare Owner

















Happy Tax Day, New York. We’re taxing the rich.









BREAKING: The U.S. just introduced a bill that would make stablecoin transactions completely tax free. Right now, every time you use USDC or USDT to pay for anything, the IRS treats it like selling a stock. You owe tax on every single transaction, even if the gain is less than a penny. This bill removes that completely. If the stablecoin holds its $1 peg, there is no taxable event. You just spend it like cash. For staking rewards, the bill gives you a choice, pay tax now when you receive them, or wait up to 5 years to pay. The bill also closes a loophole where people were selling crypto at a loss just to claim a tax deduction, then immediately buying it back. To qualify, the stablecoin must be regulated under the GENIUS Act and must hold within 1% of $1.00. Not law yet. But if it passes, it will be a big win for Stablecoins.



This is exactly the kind of hype and misrepresentation that has defined cancer research and oncology for decades. After 40+ years of work and well over $100B in taxpayer funding, what’s being presented as a revolution is a survival improvement of about 6–7 months. Patients don’t even get an additional birthday. This is now being hyped by the biotech industry and amplified by academic scientists as if it represents some fundamental breakthrough. It doesn’t. What’s even more concerning is that almost no one is calling this out. The same narrative gets repeated, the same approaches get reinforced, and the same cycle continues. Billions of taxpayer dollars will continue to fund this. Venture capital will continue to flow into biotech companies built around these claims. Pharma will continue to allocate time and resources here. Healthcare expenses for the public will continue to be greater than ever. Meanwhile, entire areas of cancer research and oncology practice—particularly early detection and prevention—remain neglected.



🚨🚨🚨 RASOLUTE-302 Ph3 is POSITIVE "Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW! AMAZING news for patients with #PancreaticCancer The RAS Revolution is ON!! ir.revmed.com/news-releases/…







